Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia.
Leopoldo Pérez de IslaGerald F WattsRodrigo AlonsoJosé Luis Díaz-DíazOvidio Muñiz-GrijalvoDaniel ZambónFrancisco FuentesRaimundo de AndrésTeresa PadróJosé López-MirandaPedro MataPublished in: European heart journal (2021)
The need for AVR due to AVS is significantly increased in FH patients, particularly in those who are older and have previous ASCVD, hypertension, increased LDL-CLp(a)-years and elevated Lp(a). Reduction in LDL-C and Lp(a) together with control of hypertension could retard the progression of AVS in FH, but this needs testing in clinical trials.ClinicalTrials.gov number NCT02693548.
Keyphrases
- low density lipoprotein
- blood pressure
- aortic valve replacement
- clinical trial
- ejection fraction
- end stage renal disease
- aortic stenosis
- transcatheter aortic valve implantation
- aortic valve
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- left ventricular
- middle aged
- arterial hypertension